July 2024

Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trialsAchieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ — DiscGenics, Inc., a privately held, late-st

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: